Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial

替卡格雷 医学 阿司匹林 氯吡格雷 经皮冠状动脉介入治疗 急性冠脉综合征 冠状动脉疾病 心肌梗塞 内科学 临床终点 心脏病学 随机对照试验
作者
Pascal Vranckx,Marco Valgimigli,Peter Jüni,Christian W. Hamm,Philippe Gabríel Steg,Dik Heg,Gerrit Anne van Es,Eugène McFadden,Yoshinobu Onuma,Cokky van Meijeren,Ply Chichareon,Edouard Benit,Helge Möllmann,Luc Janssens,Maurizio Ferrario,Aris Moschovitis,Aleksander Żurakowski,Marcello Dominici,Robert‐Jan van Geuns,Kurt Huber
出处
期刊:The Lancet [Elsevier BV]
卷期号:392 (10151): 940-949 被引量:708
标识
DOI:10.1016/s0140-6736(18)31858-0
摘要

Background We hypothesised that ticagrelor, in combination with aspirin for 1 month, followed by ticagrelor alone, improves outcomes after percutaneous coronary intervention compared with standard antiplatelet regimens. Methods GLOBAL LEADERS was a randomised, open-label superiority trial at 130 sites in 18 countries. Patients undergoing percutaneous coronary intervention with a biolimus A9-eluting stent for stable coronary artery disease or acute coronary syndromes were randomly assigned (1:1) to 75–100 mg aspirin daily plus 90 mg ticagrelor twice daily for 1 month, followed by 23 months of ticagrelor monotherapy, or standard dual antiplatelet therapy with 75–100 mg aspirin daily plus either 75 mg clopidogrel daily (for patients with stable coronary artery disease) or 90 mg ticagrelor twice daily (for patients with acute coronary syndromes) for 12 months, followed by aspirin monotherapy for 12 months. Randomisation was concealed, stratified by centre and clinical presentation (stable coronary artery disease vs acute coronary syndrome), and blocked, with randomly varied block sizes of two and four. The primary endpoint at 2 years was a composite of all-cause mortality or non-fatal centrally adjudicated new Q-wave myocardial infarction as assessed by a core lab in a blinded manner. The key secondary safety endpoint was site-reported bleeding assessed according to the Bleeding Academic Research Consortium criteria (grade 3 or 5). Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT01813435, and is closed to new participants, with follow-up completed. Findings Between July 1, 2013, and Nov 9, 2015, 15 968 participants were randomly assigned, 7980 to the experimental group and 7988 to the control group. At 2 years, 304 (3·81%) participants in the experimental group had died or had a non-fatal centrally adjudicated new Q-wave myocardial infarction, compared with 349 (4·37%) participants in the control group (rate ratio 0·87 [95% CI 0·75–1·01]; p=0·073]). There was no evidence for a difference in treatment effects for the primary endpoint across prespecified subgroups of acute coronary syndromes and stable coronary artery disease (p=0·93). Grade 3 or 5 bleeding occurred in 163 participants in the experimental group and 169 in the control group (2·04% vs 2·12%; rate ratio 0·97 [95% CI 0·78–1·20]; p=0·77). Interpretation Ticagrelor in combination with aspirin for 1 month followed by ticagrelor alone for 23 months was not superior to 12 months of standard dual antiplatelet therapy followed by 12 months of aspirin alone in the prevention of all-cause mortality or new Q-wave myocardial infarction 2 years after percutaneous coronary intervention. Funding AstraZeneca, Biosensors, and The Medicines Company.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
CodeCraft应助明天好采纳,获得10
刚刚
JamesPei应助mmx采纳,获得10
刚刚
庸人自扰发布了新的文献求助10
刚刚
科研通AI5应助茄子要吃肉采纳,获得10
1秒前
1秒前
靓丽傲玉完成签到 ,获得积分10
1秒前
小蘑菇应助吴可佳采纳,获得10
2秒前
2秒前
陌上之心完成签到,获得积分10
2秒前
石头完成签到,获得积分20
2秒前
2秒前
2秒前
夏老师发布了新的文献求助10
3秒前
狂野的河马完成签到,获得积分10
3秒前
4秒前
Excuseme发布了新的文献求助10
4秒前
冰怡霖完成签到,获得积分10
4秒前
合适磬完成签到,获得积分10
4秒前
勤奋的松鼠完成签到,获得积分10
4秒前
ASD应助jinqiaoyi采纳,获得10
5秒前
5秒前
今后应助给我一个公式吧采纳,获得10
5秒前
背后的鹭洋完成签到,获得积分10
6秒前
6秒前
xiaobai完成签到,获得积分10
6秒前
6秒前
6秒前
淡淡的发卡完成签到,获得积分10
7秒前
7秒前
汉堡包应助花生米采纳,获得10
7秒前
kaka发布了新的文献求助10
7秒前
7秒前
8秒前
暗黑同学完成签到,获得积分10
8秒前
8秒前
8秒前
科研通AI5应助哈哈哈哈采纳,获得10
8秒前
苗条画板发布了新的文献求助10
9秒前
荣不弱发布了新的文献求助10
9秒前
晚风发布了新的文献求助10
9秒前
高分求助中
(应助此贴封号)【重要!!请各位详细阅读】【科研通的精品贴汇总】 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
F-35B V2.0 How to build Kitty Hawk's F-35B Version 2.0 Model 2000
줄기세포 생물학 1000
The Netter Collection of Medical Illustrations: Digestive System, Volume 9, Part III - Liver, Biliary Tract, and Pancreas (3rd Edition) 600
Founding Fathers The Shaping of America 500
中国减肥产品行业市场发展现状及前景趋势与投资分析研究报告(2025-2030版) 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 物理化学 基因 催化作用 遗传学 冶金 电极 光电子学
热门帖子
关注 科研通微信公众号,转发送积分 4516246
求助须知:如何正确求助?哪些是违规求助? 3960341
关于积分的说明 12275345
捐赠科研通 3622886
什么是DOI,文献DOI怎么找? 1993711
邀请新用户注册赠送积分活动 1030033
科研通“疑难数据库(出版商)”最低求助积分说明 920859